Żak, K.; Satora, M.; Skrabalak, I.; Tarkowski, R.; Ostrowska-Leśko, M.; Bobiński, M.
The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives. Cancers 2024, 16, 1063.
https://doi.org/10.3390/cancers16051063
AMA Style
Żak K, Satora M, Skrabalak I, Tarkowski R, Ostrowska-Leśko M, Bobiński M.
The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives. Cancers. 2024; 16(5):1063.
https://doi.org/10.3390/cancers16051063
Chicago/Turabian Style
Żak, Klaudia, Małgorzata Satora, Ilona Skrabalak, Rafał Tarkowski, Marta Ostrowska-Leśko, and Marcin Bobiński.
2024. "The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives" Cancers 16, no. 5: 1063.
https://doi.org/10.3390/cancers16051063
APA Style
Żak, K., Satora, M., Skrabalak, I., Tarkowski, R., Ostrowska-Leśko, M., & Bobiński, M.
(2024). The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives. Cancers, 16(5), 1063.
https://doi.org/10.3390/cancers16051063
